Phase I Trial of Intraperitoneal Administration of a) a CEA-Expressing Derivative, and b) a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer

Trial ID # NCT00408590
Phase I
Drug Class Oncolytic Viruses
Drug Name MV-NIS
Alternate Drug Names oncolytic measles virus encoding thyroidal sodium iodide symporter
Drugs in Trial MV-NIS
Eligible Participant

Platinum resistant or refractory ovarian cancer

Patients Enrolled

16; median 4 prior therapies (1-8)

Therapy Setting


Study Design

Open-Label, Non-randomized


ORR, OS, evaluated per RECIST


DCR: 81.3% (13SD, n=16)
Median duration of SD: 2.2 months (1.8-9.2)
2 patients had decreasing CA125 levels
OS: 26.5 months

Clinically Significant Adverse Events

Serious AE: None
Grade 3-4 AE: None


Intraperitoneal administration of MV-NIS is safe with early evidence of antitumor activity and treatment with MV-NIS augments endogenous immunity against tumor antigens


Galanis E et al. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res (2015) 75(1):22-30

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.